COHANCE · NSE
Not in active coverage. Cited reporting has mentioned Cohance Lifesciences, the record of those mentions is below. Your interest is logged; coverage expands by demand.
Cohance Lifesciences Group CEO Umang Vohra stated that the company expects improvement in Q2 and a return to year-on-year growth from the second half.
Umang Vohra, former Cipla chief, was appointed by Advent International as executive chairman and Group CEO of Cohance Lifesciences in April 2026, succeeding Vivek Sharma.
This page lists where cited reporting has mentioned Cohance Lifesciences. It is not the full dossier: developments here are single mentions, not corroborated records. We compile and cite; we do not opine.
fregime is informational research software. Content on this page is factual reporting compiled from cited public sources; nothing here is advice, and nothing here expresses an opinion on any security. fregime is not registered with SEBI as an investment adviser or research analyst. Before making investment decisions, consult a SEBI-registered adviser. Price figures are delayed end-of-day values cited to the exchange's published file, never live quotes.